Search

Your search keyword '"BRILOT, FABIENNE"' showing total 477 results

Search Constraints

Start Over You searched for: Author "BRILOT, FABIENNE" Remove constraint Author: "BRILOT, FABIENNE"
477 results on '"BRILOT, FABIENNE"'

Search Results

2. Infection and Vaccine Induced Spike Antibody Responses Against SARS-CoV-2 Variants of Concern in COVID-19-Naïve Children and Adults

5. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria

6. Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19

7. Oral corticosteroid dosage and tapeduration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse

8. Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia

11. Myelin-oligodendrocyte glycoprotein antibody-associated disease

12. Maternal autoimmunity and inflammation are associated with childhood tics and obsessive-compulsive disorder: Transcriptomic data show common enriched innate immune pathways

14. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease

15. Cross-Sectional and Longitudinal Genotype to Phenotype Surveillance of SARS-CoV-2 Variants Over the First Four Years of the COVID-19 Pandemic

16. International MOGAD criteria

18. The clinical profile of NMOSD in Australia and New Zealand

20. TMPRSS2 activation of Omicron lineage Spike glycoproteins is regulated by TMPRSS2 cleavage of ACE2

21. 8 Dosing of oral corticosteroid therapy and the risk of relapse at the onset of MOGAD

22. 6 Spike antibody seroconversion and emerging variant cross-reactivity following COVID-19 third vaccination dose in Australian people with multiple Sclerosis

25. A longitudinal analysis of brain volume changes in myelin oligodendrocyte glycoprotein antibody‐associated disease.

26. International multicenter examination of MOG antibody assays

27. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants

28. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level

29. Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF

30. Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination

32. Humoral signatures of MOG-antibody-associated disease track with age and disease activity

33. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sublineages in the face of maturing antibody breadth at the population level

34. Infection and vaccine induced Spike antibody responses against SARS-CoV-2 Variants of concern in immune naïve children and adults

36. MOGAD Scoping Review

37. 2432 Spike antibody seroconversion and breadth following SARS-CoV-2 vaccination in Australian people with Multiple Sclerosis

39. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination

40. Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV ‐2 variants, but preserved antigen‐specific T cell responses

42. Clonal dynamics of SARS-CoV-2-specific T cells in children and adults with COVID-19

43. sj-docx-2-mso-10.1177_20552173211063126 - Supplemental material for Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis

44. Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV‐2 variants, but preserved antigen‐specific T cell responses

45. sj-docx-1-mso-10.1177_20552173211063126 - Supplemental material for Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis

46. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

47. Emergence and Antibody Evasion of BQ and BA.2.75 SARS-CoV-2 Sublineages in the Face of Maturing Antibody Breadth at the Population Level

48. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

49. Reply to “Investigating the immunopathogenic mechanisms underlying MOGAD ”

50. Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia

Catalog

Books, media, physical & digital resources